Ann: IND QUESTIONS RECEIVED FROM US FDA, page-247

Scenario 1 is, IMHO, the option we should see, and I would be disappointed, as will the market if we don't see it today, or at least by 30 June.
Unfortunately, this stock only moves on 2 things, News, or lack of News. Those of us invested understand that, and the associated risks.
I think if we don't see Scenario 1, asap, we may test fresh lows, maybe near $1.50 which was the May 2020 (COVID) low. I am not down ramping, you know I am a holder and a believer and have a strategy to buy more on any weakness.
I think the IND is extremely important as a milestone and perhaps signal to the larger pool of investors (institutional) that PAR is a company with enormous long term capital growth prospects. Any delay, failure, of IND even with justification, will be a significant set back IMHO. DYOR. GLTAH.